

## Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels

<sup>1</sup>Hesham Nabil and <sup>2</sup>Aziza Abdulaziz and <sup>3</sup>Ahmed Fikry

<sup>1</sup>Department of Andrology, Menoufiya University, <sup>2</sup>Clinical Pathology Department, Medical Centre, Abu Dhabi, United Arab Emirates.

**Abstract:** Objective: To study the potential impact of vardenafil when given in a daily dose on the semen parameters and sex hormones levels of erectile dysfunction (ED) patients. Setting: Andrology Clinic - Dr. Ahmad Fikry Medical Centre, Abu Dhabi, United Arab Emirates. Patients: Forty male subjects complaining of erectile dysfunction were enrolled in the study from November 2007 - May 2008. Intervention: All recruited subjects were subjected to semen analysis and measurement of sex hormones levels that is done before and then after 4 months of continuous daily use of vardenafil 20 mg in the first group or placebo in the second group. Results: No statistically significant differences were observed in the seminal parameters or in the hormonal levels in ED patients done before and after vardenafil therapy. Conclusions: Vardenafil is largely a safe new medication for erectile dysfunction that has no serious impact on neither seminal parameters nor sex hormonal levels of treated patients.

**Key words:** Vardenafil, Erectile Dysfunction, seminal and Hormonal Levels

### INTRODUCTION

Erectile dysfunction (ED) is a common condition that is associated with increasing age and the presence of many medical conditions, including cardiovascular disease and diabetes mellitus (Hedelin H. and P. Stroberg, 2005). Although other management options are now available, oral pharmacotherapy with a phosphodiesterase type 5 (PDE5) inhibitor is currently the first choice of most physicians and patients for the treatment of ED (Mulhall J.P. and F. Montorsi, 2006).

Currently, there are three PDE5 inhibitors available, namely sildenafil, vardenafil and tadalafil, and all have demonstrated efficacy and tolerability in a wide range of ED populations (Goldstein I., J.M. Young, *et al*, 2003). Vardenafil is a PDE5 inhibitor that induces cGMP accumulation in human Corpus cavernosum, thus potentiating NO-induced penile erection in ED men (Porst H., R. Rosen, N.H. Padma, *et al*, 2001). As with other PDE5 inhibitors, vardenafil is taken on demand before commencing the sexual act (Stief C., H. Porst, 2004), but little is known about its use on daily basis in ED men nowadays and its effects on their body functions with this new regimen.

The aim of the present study is to investigate whether the daily dosing of vardenafil in ED patients could possibly have any potential serious effect on seminal parameters as well as sex hormonal levels of those ED patients treated.

### MATERIALS AND METHODS

Forty male subjects complaining of erectile dysfunction were selected from Andrology Clinic, Ahmad Fikry Medical Centre, Abu Dhabi, United Arab Emirates. The study covered the period from November 2007 - May 2008. All selected subjects gave written consent for participation in the study. All ED patients had a score < 20 (Table 1) on the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) calculated as the sum of scores from questions 1-5 and 15. The following were done for all the patients:

1. Detailed medical and sexual history.
2. Thorough medical examination.
3. Duplex study of the cavernosal arteries.

**Corresponding Author:** Hesham Nabil, Department Of Andrology, Menoufiya University, Egypt.  
E-mail: heshamnk@hotmail.com.

The recruited subjects were divided into two major groups:

- Group one comprising twenty men who received vardenafil 20 mg tabs. daily for 4 months.
- Group two comprising twenty men who received a placebo daily for 4 months.

**Table 1:** showing baseline patient demographics.

| Parameters                                   | Placebo (N=20) | Vardenafil (N=20) |
|--|----------------|-------------------|
| Mean age, years                              | 53.2           | 54.1              |
| Mean BMI, Kg/m <sup>2</sup>                  | 26.9           | 26.2              |
| Mean duration since ED diagnosis made, years | 3.2            | 2.9               |
| Mean baseline IIEF-EF score                  | 15.3           | 14.9              |
| Comorbid conditions, %                       |                |                   |
| Hypertension                                 | 40             | 50                |
| Diabetes                                     | 25             | 30                |
| Hyperlipidemia                               | 20             | 20                |
| Aetiology of ED, %                           |                |                   |
| Organic                                      | 25             | 27                |
| Psychogenic                                  | 23             | 20                |
| Mixed  | 52             | 53                |

The ED patients were selected according to the following inclusion criteria:

- Gave a history of ED during the past 6 months.
- Age ranges from 18-60 ys.
- Indulged in a stable heterosexual relationship at least for the past 6 months.
- History of current use of PDE5 inhibitors or any ED therapy is negative for the past 3 months.
- Compliant cooperative patient with fairly stable personality, who can afford vardenafil daily.

The following exclusion criteria were strictly applied throughout the study:

- Patients with history of unstable angina, myocardial infarction, congestive heart failure, serious and/or uncontrolled arrhythmias or stroke during the past 6 months.
- Patients with chronic liver disease for the past 6 months or abnormal liver functions.
- Patients with persistently high serum creatinine >2.0 mg/dl.
- Patients with abnormal thyroid function whether hypo- or hyperthyroidism.
- Patients with uncontrolled diabetes.
- Patients with clinically or serologically demonstrable haematological disease.
- Patients with moderate-severe penile anatomical abnormalities that significantly interfere with erection.
- Patients with retinitis pigmentosa or other inherited eye diseases.
- Patients using androgens, anti-androgens, anti-coagulants or anti-depressants for the past 3 months, patients under nitrate therapy.
- Patients receiving medications that interfere with cytochrome CYP 450 3A4.
- Patients having serum total testosterone >10% below lower limit of normal.
- Patients with unstable psychiatric condition or on substance abuse and/or addiction.

For both groups, semen analysis and measurement of sex hormones levels were done before and at the end of the study.

Semen analysis was processed according to the WHO guidelines with abstinence period of 48 hrs., using the masturbation technique, collected at a special room and immediately delivered to the lab. Sex hormones levels namely LH, FSH and testosterone were measured using Eliza technique (Mini Vidas, BioMérieux, Italy). The normal range for LH and FSH accepted was 1-10 IU/ml while that for testosterone was 3-10.6 ng/ml.

All the results were analysed using windows SPSS version 10 employing paired-t-test and independent t-test.

## **RESULTS AND DISCUSSION**

Erectile dysfunction is a frequent age-related disorder resulting from a combination of organic and psychologic factors (Saenz de Tejada I., J. Angulo, *et al*, 2005). Erectile dysfunction has a profound effect on man's sense of self and quality of life. Men also report that ED affects not only the emotional intimacy in their primary relationship, but also their daily interactions with women or other potential partners (Latini D.M., D.F. Penson, *et al*, 2002). It has been estimated that ED currently affects 152 million men worldwide, and this number is estimated to reach 322 million by 2025 (Ayta I.A., *et al*, 1999).

With the revolutionary introduction of oral therapy (sildenafil, the first PDE5 inhibitor) for ED at the end of the previous decade, a safe and effective treatment, in many ways mimicking natural erection became available (Gonzalzo M.L., M. Brotzman, *et al*, 2003). This has led to an increasing number of patients seeking treatment for their ED (Fisher W.A., R.C. Rosen, 2004).

Vardenafil (levitra®) is the latest member of the PDE5 inhibitors family released at the market just few years after launching of its first pioneer product, namely sildenafil citrate. Vardenafil is a potent and highly selective PDE5 inhibitor. Vardenafil improved erectile function in men with mild to severe ED of varying aetiology and it is generally well tolerated with few side effects that are typical of PDE5 inhibitors although they are mild to moderate in intensity and transient in nature (Edwards D., Hackett, 2006; Padma-Nathan H., 2007; Tan H.M., C.M. Chin, 2008).

Phosphodiesterase 5 catalyses the breakdown of cGMP which is the most abundant second messenger in the human Corpus cavernosum. By hydrolyzing the phosphodiesterase bond of cGMP, cGMP is converted into the biologically-inactive monophosphate, resulting in termination of its physiologic function (Küthe A., *et al*, 2001) Vardenafil as a highly selective PDE5 inhibitor blocks previous step resulting in accumulation of cGMP that facilitates and potentiates relaxation of cavernosal and vascular smooth muscle cells, thus eventually terminating with satisfactory penile erection (Corbin J.D., 2004).

Vardenafil like other members of its group is given on-demand basis mainly i.e. the patient receives his dose whenever he decides to have sexual relation with his partner.

Vardenafil works as early as 11 minutes after intake with extended efficacy up to 8 h. postdose (Montorsi F., H. Padma-Nathan, 2004).

Having stated that, daily dosing of PDD5 inhibitors at bed time became a successful treatment option in early sexual rehabilitation of patients after nerve-sparing radical prostatectomy (NSRP) (Schwartz E.J., P. Wong, 2004). Later on, daily dosing with PDE5 inhibitors turned out to be very successful in non-responders to on-demand treatment (McMahon C., 2004).

Although this was proven true for sildenafil and tadalafil, it certainly can be assumed that this also holds true for all PDE5 inhibitors including vardenafil, in particular in patients with severe organic ED (Hartmut Port, 2006).

In the current study, 40 ED patients were classified to receive either daily dosing with vardenafil 20 mg or placebo for 4 consecutive months.

For the assumed effect of chronic daily dosing of vardenafil on seminal parameters namely sperm count, motility and percentage of abnormal morphology, no statistically significant difference was found between predose and postdose measurements for vardenafil group as shown in Table (2).

**Table 2:** showing that for both vardenafil and placebo groups, comparing the pretest and posttest values of seminal parameters and sex hormonal levels are statistically insignificant ( $P>0.05$ ) using paired- t test.

| Parameters | Paired Differences                                   |                |                 | 95% Confidence interval |           | t         | df     | S i g .<br>(2-tailed) |       |
|------------|--|----------------|-----------------|-------------------------|-----------|-----------|--------|-----------------------|-------|
|            | -----  |                |                 | of the Difference       |           |           |        |                       |       |
|            | Mean   | Std. Deviation | Std. Error Mean | Lower                   | Upper     |           |        |                       |       |
| Pair 1     | E.D. Var Before (Sp Conc) - E.D. Var After (Sp Conc) | -5750          | 1.8728          | .4188                   | -1.4515   | .315      | -1.373 | 19                    | .186  |
| Pair 2     | E.D. PI Before (Sp Conc) - E.D. PI After (Sp Conc)   | -.9550         | 1.9720          | .4410                   | -1.8779   | -.21E-02  | -2.166 | 19                    | 0.073 |
| Pair 3     | E.D. Var Before (Sp Mot) - E.D. Var After (Sp Mot)   | 8.500E-03      | 4.416E-02       | 9.875E-03               | -1.22E-02 | 2.917E-02 | .861   | 19                    | 400   |
| Pair 4     | E.D. PI Before (Sp Mot) - E.D. PI After (Sp Mot)     | 4.150E-02      | .1594           | 3.565E-03               | -3.31E-02 | .1161     | 1.164  | 19                    | 0259  |
| Pair 5     | E.D. Var Before (Ab Sp) - E.D. Var After (Ab Sp)     | -1.05E-02      | 1.605E-02       | 3.589E-03               | -1.80E-02 | 2.99E-03  | -2.926 | 19                    | 0.259 |
| Pair 6     | E.D. PI Before (Ab Sp) - E.D. PI After (Ab Sp)       | -4.00E-03      | 1.635E-02       | 3.656E-03               | -1.17E-02 | 3.653E-03 | -1.094 | 19                    | .288  |
| Pair 7     | E.D. Var Before (LH)-E.D. Var After (LH)             | 2.3800         | 10.6443         | 2.3801                  | -2.6017   | 7.3617    | 1.000  | 19                    | .330  |
| Pair 8     | E.D. PI Before (LH)-E.D. PI After (LH)               | -2.00E-02      | .1196           | 2.675E-02               | -7.60E-02 | 3.600E-02 | -.748  | 19                    | .464  |
| Pair 9     | E.D. Var Before (FSH) - E.D. Var After (FSH)         | 1.8150         | 18.6662         | 4.1739                  | -6.9210   | 10.5510   | .435   | 19                    | .669  |
| Pair 10    | E.D. PI Before (FSH)-E.D. PI After (PSH)             | -1.50E-02      | .1137           | 2.542E-02               | -6.82E-02 | 3.820E-02 | -.590  | 19                    | .562  |
| Pair 11    | E.D. Var Before (Testo) - E.D. Var After (Testo)     | -.2100         | .9668           | .2162                   | -.6625    | .2425     | -.971  | 19                    | .344  |
| Pair 12    | E.D. PI Before (Testo) - E.D. PI After (Testo)       | -2.50E-02      | .1251           | 2.798E-02               | -8.36E-02 | 3.356E-02 | -.893  | 19                    | .383  |

Regarding the assumed effect of chronic daily dosing of vardenafil on sex hormonal levels namely LH, FSH and testosterone. Again, no statistically significant difference was found between predose and postdose measurements in the vardenafil group as shown in Table (2).

Also, comparing the predose and postdose measurements of both vardenafil and placebo groups does not reveal any statistically significant difference in connection with seminal parameters or with sex hormonal levels as shown in Table (3).

**Table 3:** Showing that comparing the mean values of pretest and posttest measurements of vardenafil group versus placebo group are statistically insignificant ( $P>0.05$ ) using independent t-test.

| Parameters                  | Levene's Test for Equality of Variances |      | t-test for Equality of Means |        |                 |                  |                        |   |           |
|-----------------------------|---|------|------------------------------|--------|-----------------|------------------|------------------------|---|-----------|
|                             | F                                       | Sig. | t                            | df     | Sig. (2-tailed) | Mean Differ-ence | Std. Error Differ-ence | 95% Confidence Interval of the Difference |           |
|                             |   |      |                              |        |                 |                  |                        | Lower                                     | Upper     |
| SP Conc Before              |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | .778                                    | .383 | 1.273                        | 38     | .211            | 11.1300          | 8.7452                 | -6.573                                    | 28.8337   |
| Equal variances not assumed |   |      | 1.273                        | 37.112 | .211            | 11.1300          | 8.7452                 | -6.5876                                   | 28.8476   |
| SP Conc After               |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | .638                                    | .429 | 1.213                        | 38     | .232            | 10.7500          | 8.8593                 | -7.1848                                   | 28.6848   |
| Equal variances not assumed |   |      | 1.213                        | 37.249 | .233            | 10.7500          | 8.8593                 | 7.1967                                    | 28.6967   |
| SP Mot Before               |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 1.533                                   | .223 | -.498                        | 38     | .621            | -3.7000E-02      | 7.430E-02              | -.1874                                    | .1134     |
| Equal variances not assumed |   |      | -.498                        | 3.384  | .622            | -3.7000E-02      | 7.430E-02              | -.1876                                    | .1136     |
| SP Mot After                |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 2.355                                   | .133 | -0.59                        | 38     | .953            | -4.0000E-03      | 6.748E-02              | -.1406                                    | .1326     |
| Equal variances not assumed |   |      | -0.59                        | 35.879 | .953            | -4.0000E-03      | 6.748E-02              | -.1409                                    | .1329     |
| Ab Sp Before                |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 3.266                                   | .079 | -1.704                       | 38     | .096            | -.1160           | 6.806E-02              | -.2538                                    | 2.177E-02 |
| Equal variances not assumed |   |      | -1.704                       | 34.054 | .097            | -.1160           | 6.806E-02              | -.2543                                    | 2.230E-02 |
| Ab Sp After                 |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 2.542                                   | .119 | -1.602                       | 38     | .118-.1095      | 6.837E-02        | -.2479                 | 2.890E-02                                 |           |
| Equal variances not assumed |   |      | -1.602                       | 34.762 | .118            | -.1095           | 6.837E-02              | -.2483                                    | 2.932E-02 |
| LH Before                   |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 1.691                                   | .201 | .661                         | 38     | .5121.6800      | 2.5404           | -3.4628                | 6.8228                                    |           |
| Equal variances not assumed |   |      | .661                         | 20.586 | .516            | 1.6800           | 2.5404                 | -3.6096                                   | 6.9696    |
| LH After                    |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | .945                                    | .337 | -1.103                       | 38     | .227            | -.7200           | .6528                  | -2.0414                                   | .6014     |
| Equal variances not assumed |   |      | -1.103                       | 36.575 | .277            | -.7200           | .6528                  | -2.0431                                   | .6031     |
| PSH Before                  |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 3.263                                   | .079 | 1.042                        | 38     | .304            | 3.6850           | 3.5374                 | -3.4760                                   | 10.8460   |
| Equal variances not assumed |   |      | 1.042                        | 19.815 | .310            | 3.6850           | 3.5374                 | -3.6982                                   | 11.0682   |
| PSH After                   |   |      |                              |        |                 |                  |                        |   |           |
| Equal variances Assumed     | 1.555                                   | .220 | .761                         | 38     | .452            | 1.8550           | 2.4386                 | -3.0817                                   | 6.7917    |
| Equal variances not assumed |   |      | .761                         | 20.803 | .455            | 1.8550           | 2.4386                 | -3.2193                                   | 6.9293    |

**Table 3:** Continued.

|                             |       |      |       |        |      |        |       |         |       |
|-----------------------------|-------|------|-------|--------|------|--------|-------|---------|-------|
| Testo Before                |       |      |       |        |      |        |       |         |       |
| Equal variances Assumed     | .052  | .820 | -.794 | 38     | .432 | -.5350 | .6742 | -1.8999 | .8299 |
| Equal variances not assumed |       |      | -.794 | 37.968 | .432 | -.5350 | .6742 | -1.8999 | .8299 |
| Testo After                 |       |      |       |        |      |        |       |         |       |
| Equal variances Assumed     | 1.063 | .309 | -5.68 | 38     | .573 | -.3500 | .6159 | -1.5968 | .8968 |
| Equal variances not assumed |       |      | -.568 | 35.848 | .573 | -.3500 | .6159 | -1.5993 | .8993 |

Our results are in agreement with that of Jarvi *et al.* (2008) who found that vardenafil given as 20 mg daily has no noticeable effect on semen parameters or on reproductive hormones when compared with placebo. We believe that daily nightly dosing with vardenafil would become the mainstay in the future for the treatment of ED patients especially those with severe organic ED and non-responders to the usual on-demand PDE5 inhibitor dosage even when given at the maximum therapeutic dose. On the contrary, some recent studies have demonstrated that daily vardenafil has comparable efficacy to on-demand regimen (Montorsi F., G. Brock, J. Lee, *et al.*, 2008; Zumbé J., H. Porst, 2008). We do believe that such point needs further detailed studies as the first study focused on NSRP-induced ED men only while the second study focused on men with mild-moderate ED only and both studies did not include more difficult-to-treat organic ED or mixed-aetiology cases. Besides, chronic dosing with PDE5 inhibitors resulted in improvement of endothelial dysfunction. This holds true not only for the cavernous bodies, but also for the endothelium of the whole vascular system (Behr-Roussel D., D. Gorny, 2008; Behr-Roussel D., D. Gorny, 2005).

#### Conclusions:

Vardenafil is a potent and highly selective PDE5 inhibitor. It is largely a safe drug when given in chronic daily dosing with no demonstrable effects on ED men regarding their seminal parameters or their sex hormonal profile. Such findings may open a new frontier in the treatment of severe ED cases in the era of PDE5 inhibitors.

#### REFERENCES

- Hedelin, H. and P. Stroberg, 2005. Treatment for erectile dysfunction based on patient-reported outcomes: To every man the PDE5 inhibitor that he finds superior. *Drugs*, 65: 2245-51.
- Mulhall, J.P. and F. Montorsi, 2006. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. *Eur. Urol.*, 49: 30-7.
- Goldstein, I., J.M. Young, *et al.*, 2003. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. A multi-center double-blind placebo-controlled fixed-dose study. *Diabetes Care*, 26: 777-83.
- Porst, H., R. Rosen, N.H. Padma, *et al.*, 2001. The efficacy and tolerability of vardenafil, a new oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. *Int. J. Impot. Res.*, 13: 192-9.
- Stief, C., H. Porst, I. Saenz de Tejada, *et al.*, 2004. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. *Int. J. Clin. Pract.*, 58: 230-239.
- Saenz, de Tejada I., J. Angulo, *et al.*, 2005. Pathophysiology of erectile dysfunction. *J. Sex. Med.*, 2: 26-39.
- Latini, D.M., D.F. Penson, *et al.*, 2002. Psychological impact of erectile dysfunction: Validation of a new health related quality of life measure for patients with erectile dysfunction. *J. Urol.*, 168: 2086-91.
- Ayta, I.A., *et al.*, 1999. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. *BJU Int.*, 84: 50-6.
- Gonzalzo, M.L., M. Brozman, *et al.*, 2003. Clinical efficacy of sildenafil citrate and predictors of long-term response. *J. Urol.*, 170: 503-6.
- Fisher, W.A., R.C. Rosen, I. Eardley, *et al.*, 2004. The multinational Men's Attitude to life events and sexuality (males) study phase II: Understanding PDE5 inhibitor treatment seeking patterns among men with erectile dysfunction. *J. Sex Med.*, 1: 150-60.
- Edwards, D., Hackett, O. Collins, *et al.*, 2006. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED). A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partners. *J. Sex Med.*, 3: 1028-36.

Padma-Nathan, H., F. Montorsi, F. Giuliano, *et al*, 2007. Vardenafil restores erectile dysfunction to normal range in men with erectile dysfunction. *J. Sex Med.*, 4(1): 152-61.

Tan, H.M., C.M. Chin, C.B. Chua, *et al*, 2008. Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. *Asian J. Androl.*, 10(3): 495-502.

Küthe, A., *et al*, 2001. Expression of different phosphodiesterase genes in human cavernosum smooth muscle. *J. Urol.*, 165: 280-283.

Corbin, J.D., 2004. Mechanism of action of PDE-5 inhibition in erectile dysfunction. *Int J. Impot. Res.*, 16: 54-57.

Montorsi, F., H. Padma-Nathan, J. Buvat, *et al*, 2004. Earliest time of action leading to successful intercourse with vardenafil determined in an at-home setting. a randomized, double-blind, placebo-controlled trial. *J. Sex Med.*, 1: 168-178.

Schwartz, E.J., P. Wong, R.J. Graydon, 2004. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. *J. Urol.*, 171: 771-774.

McMahon, C., 2004. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. *J. Sex Med.*, 1: 292-300.

Hartmut Port, 2006. Oral pharmacotherapy of erectile dysfunction. In: Hartmut Porst and Jacques Buvat, eds. *Standard practice in sexual medicine*. Blackwell Publishing, Chapter, 7: 75-93.

Jarvi, K., E. Dula, J. Pryor, *et al*, 2008. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with baseline levels. *J. Urol.*, 179: 1060-5.

Montorsi, F., G. Brock, J. Lee, *et al*, 2008. Effect of nightly versus on demand vardenafil on recovery of erectile dysfunction in men following bilateral nerve sparing radical prostatectomy. *Eur. Urol.*, 54: 235-243.

Zumbé J., H. Porst, F. Sommer, *et al*, 2008. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: Findings of the RESTORE study. *Eur. Urol.*, 54: 204-12.

Behr-Roussel, D., D. Gorny, K. Mevel, *et al*, 2008. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. *Eur. Urol.*, 47: 87-91.

Behr-Roussel, D., D. Gorny, C. Vitale, *et al*, 2005. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. *Eur. Urol.*, 47: 214-222.